Anti Virus Trial -

Elena’s team had spent three years developing a broad-spectrum antiviral compound, code-named AVI-7. It worked differently from existing drugs: rather than targeting viral surface proteins (which mutate rapidly), AVI-7 attached to a host cell protein that the virus needed to replicate. In theory, this made it “resistance-proof.” But theory was not evidence.

With regulatory approval, 40 healthy volunteers received ascending doses of AVI-7 at a hospital in Oslo. The goal: find side effects. Most reported mild nausea. Two developed temporary liver enzyme elevations, setting a maximum safe dose. No one died. No one got sick from the virus because they were never exposed to it. anti virus trial

The trial that followed was a masterclass in scientific caution and ethics. Elena’s team had spent three years developing a